echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Don't stop supplying! Good news for the unselected products with volume purchase

    Don't stop supplying! Good news for the unselected products with volume purchase

    • Last Update: 2020-01-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [industry trends of pharmaceutical network] recently, Zhejiang Medical Insurance Bureau and Zhejiang health and Health Commission jointly issued a notice asking hospitals to put an end to the practice of purchasing and using only the same generic name selected drugs and stopping the supply of non selected drugs in order to ensure the agreed purchase volume Don't stop supplying! According to the good news (picture source: pharmaceutical network) Notice on the volume purchase of unselected varieties, medical institutions must also guarantee the reasonable drug use needs of the non unselected drug masses while ensuring that the selected drugs enter the hospital and are used preferentially Local hospitals must plan to purchase and use the selected and non selected drugs to avoid the situation that only the selected drugs or non selected drugs are supplied In addition, more efforts will be made to monitor procurement and use It is understood that this document issued by Zhejiang Province requires medical institutions not to suspend the purchase of non selected varieties, which is based on a series of problems caused by some medical institutions in implementing the agreed purchase volume of selected drugs for centralized purchase in the implementation of centralized purchase alliance centralized purchase For example, in the case of drugs with the same generic name, only the selected drugs are purchased and used, and the supply of non selected drugs is stopped, which makes it difficult for patients to buy non selected drugs At present, it is not known whether other provinces will take the same action in the future, but this timely adjustment must have given a temporary reassurance to enterprises like Beijing New Pharmaceutical Co., Ltd and Jialin Pharmaceutical Co., Ltd., which have not been selected The industry insiders said that the problems faced by Zhejiang in this time should be the problems faced by all regions carrying out volume procurement If we want to solve this problem fundamentally, we can only hope that the core unified medical insurance payment standard will be issued as soon as possible, or the separate medical insurance payment standard for purchasing drugs with volume will be issued and implemented as soon as possible But for the non selected enterprises, these policies have not yet been affected, and greater challenges are coming It is expected that the second round of national centralized purchase, which will be opened on January 17, will be adjusted in terms of the number of selected enterprises and the selection criteria For example, there are only four out of five bidding enterprises in the knockout competition In theory, if the bidding price is lower than one of them, the bidding enterprises can win the bid But in fact, due to the information asymmetry, the enterprises do not know the product cost between each other, so the result of the "non cooperation" game will inevitably lead to everyone to quote the cost price and enter the price war again Next, with the continuous deepening of volume purchase, many drug prices will be squeezed out In addition to the reduction of profits of a group of enterprises, the industry concentration will be further deepened, and many small and medium-sized pharmaceutical enterprises will be eliminated Therefore, under such industry reshuffle, enterprises must realize that the era of relying on marketing to play the world has gone forever In the process of transformation and upgrading, they need to focus on their core capabilities as soon as possible, or improve production efficiency, or conduct new drug research and development, or do a good job in services In 2020, the industry believes that it will be a key year for the combination of various medical reform measures to attack, a year for the real storm of centralized drug procurement after the medical insurance bureau's bid invitation and purchase, and a year for testing the endurance and determination of pharmaceutical enterprises In the future, only persistence can win vitality Only by strengthening their own management and opening up resources and reducing expenditure can pharmaceutical enterprises have the capital to persist in victory.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.